Indications :
- Myelofibrosis
- Polycythemia vera
- Acute graft versus host disease
- Chronic GVHD
Product Introduction :
Ruxolitinib is used to treat myelofibrosis (a cancer of the bone marrow in which the bone marrow is replaced by scar tissue and causes decreased blood cell production). It is also used to treat polycythemia vera (PV; a slow growing cancer of the blood in which the bone marrow makes too many red blood cells) in people who were not able to be treated successfully with hydroxyurea. Ruxolitinib is also used to treat acute graft versus host disease (aGVHD; a complication of hematopoietic stem-cell transplant [HSCT; a procedure that replaces diseased bone marrow with healthy bone marrow] that usually develops within the first months after HSCT) in adults and children 12 years of age and older who were treated unsuccessfully with steroid medications. It is also used to treat chronic GVHD (cGVHD; a complication of HSCT that usually develops at least 3 months after HSCT) in adults and children 12 years of age and older who were treated unsuccessfully with 1 or 2 other treatments. Ruxolitinib is in a class of medications called kinase inhibitors. It works to treat myelofibrosis and PV by blocking the signals that cause cancer cells to multiply. This helps to stop the spread of cancer cells. It works to treat GVHD by blocking the signals of the cells that cause GVHD.
Administration and Dosage :
The dose should be adjusted according to platelet count.
Initial dose:
- platelet >200x10^9, 20mg twice daily:
- platelet 100x10^9-200x10^9, 15mg twice daily;
- Platelet 50x10^9-100x10^9, 5mg twice daily:
Maximum dose:
- Platelet >100x10^9, 25mg twice daily:
- Platelet 50x10^9-100x10^9, twice daily, 10mg each time.
